bioRxivCancer BiologyPreprint
C-terminal HSP90 Inhibitors Block the HSP90:HIF-1a Interaction and Inhibit the Cellular Hypoxic Response
Abstract
Hypoxia Inducible Factor (HIF) is a transcription factor activated by low oxygen, which is common in solid tumours. HIF controls the expression of genes involved in angiogenesis, chemotherapy resistance and metastasis. The chaperone HSP90 (Heat Shock Protein 90) stabilizes the subunit HIF-1 and prevents degradation. Previously identified HSP90 inhibitors bind to the N-terminal pocket of HSP90 which blocks binding to HIF-1, and produces HIF-1 degradation. N-terminal inhibitors have failed in the clinic as single therapy treatments due in part because they induce a heat shock response, which increases chemotherapy resistance. SM molecules are HSP90 inhibitors that bind to the C-terminus and do not activate the heat shock response. The effects of C-terminal HSP90 inhibitors on HIF-1 are unreported. Herein we show that SM compounds block binding between HSP90 and HIF-1, leading to HIF-1 degradation through the proteasome using the PHD/pVHL pathway in hypoxic conditions. The SM compounds decrease HIF-1 target gene expression at the mRNA and protein level under hypoxia in colorectal cancer cells, leading to cell death, without inducing a heat shock response. Our results suggest that targeting the C-terminus of HSP90 blocks the hypoxic response and may be an effective anti-cancer strategy.
- organism: human
- assay: bulk RNA-seq
- research focus: cancer & tumor microenvironment
- research focus: differential expression
- research focus: cell type annotation
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Inhibition of the HSP90 homodimerization and HSP90-HIF1α interactions by employing small molecules at C-terminal ATP binding site of HSP90
Jagadeesha Poyya, Chandrashekhar G. Joshi·bioRxiv·Jun 2, 2024
- HIF1α inhibition by dual targeting of CDK4/6 and HSP90 reduces cancer cell viability including Rb-deficient cells
S. Zhao, L. Zhou, … W. El-Deiry·bioRxiv·Oct 20, 2020
- Enhancement of colorectal cancer therapy through interruption of the HSF1-HSP90 axis by p53 activation or cell cycle inhibition
T. Isermann, K. L. Schneider, … R. Schulz-Heddergott·bioRxiv·Feb 22, 2024
- The sensitivity to Hsp90 inhibitors of both normal and oncogenically transformed cells is determined by the equilibrium between cellular quiescence and activity
P. C. Echeverria, K. Bhattacharya, … D. Picard·bioRxiv·Nov 16, 2018
- Daily administration of low-dose daunorubicin or doxorubicin inhibits hypoxia-inducible factor 1 and tumor vascularization
Y. Yang, D. Z. Chen, … G. L. Semenza·bioRxiv·Jun 15, 2022
- USP29 is a novel non-canonical Hypoxia Inducible Factor-α activator
A. S. Schober, I. Martin-Barros, … E. Berra·bioRxiv·Feb 20, 2020